CYP2B6 and acute myeloid leukemia: They found that GT and GT + TT genotype frequencies were greater in ALL (37.5% and 42.7%, respectively, p < 0.01), and AML (37.2% and 40.9%, respectively, p < 0.01) than in control (23.9% and 25.9%, respectively), suggesting that the inherited defective function of the CYP2B6 detoxification pathway may be an important genetic determinant of leukemia risk [16].